Entera Bio Ltd.

NasdaqCM ENTX

Entera Bio Ltd. Price to Book Ratio (P/B) on December 30, 2024

Entera Bio Ltd. Price to Book Ratio (P/B) is NA on December 30, 2024, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Entera Bio Ltd. 52-week high Price to Book Ratio (P/B) is NA on December 30, 2024, which is NA below the current Price to Book Ratio (P/B).
Entera Bio Ltd. 52-week low Price to Book Ratio (P/B) is NA on December 30, 2024, which is NA below the current Price to Book Ratio (P/B).
Entera Bio Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: ENTX

Entera Bio Ltd.

CEO	Ms. Miranda J. Toledano M.B.A.
IPO Date	June 28, 2018
Location	Israel
Headquarters	Kiryat Hadassah Minrav Building
Employees	17
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Key trends

Past 5 years